EXTENDED CLASS PERIOD: Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Organon & Co. and Announces Opportunity for Investors with Substantial Losses to Lead Class Action Lawsuit – OGN

Core Viewpoint - A class action lawsuit has been filed against Organon & Co. for alleged violations of the Securities Exchange Act of 1934, claiming misleading statements regarding the company's financial health and projections during the Class Period from November 3, 2022, to April 30, 2025 [1][4]. Company Allegations - The lawsuit alleges that Organon misrepresented the risk of loss of exclusivity and price erosion for its product Nexplanon, leading to inflated sales growth expectations that would not reach the projected $1 billion by the end of fiscal year 2025 [4]. - It is claimed that Organon was not on track to achieve the necessary $1 billion in free cash flow to sustain its dividend, nor maintain a debt leverage ratio of 4.0x, which could jeopardize its corporate debt ratings [4]. - The lawsuit also states that Organon lacked a reasonable basis for reporting its business metrics and financial projections during the Class Period [4]. Financial Impact - Following the announcement of its first quarter 2025 financial results, Organon reduced its dividend by 90%, from $1.16 per share annually to $0.08 per share annually, which resulted in a stock price drop of over 27% [5].